Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
March 30 2009 - 8:09AM
PR Newswire (US)
SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced its director
nominees for election at the 2009 Annual Meeting of Stockholders.
Over the past several months, the Company's Corporate Governance
Committee, in consultation with other independent directors,
engaged in a rigorous process to identify a slate of highly
qualified and experienced nominees that the Board strongly believes
will best serve the interests of all Amylin stockholders. This
included obtaining input from many of our stockholders and a review
of potential nominees, including those proposed by stockholders and
those identified by an independent search firm. The two new
independent nominees to the Board are Paul N. Clark, former
Chairman, Chief Executive Officer and President of Icos Corporation
and Paulo F. Costa, former President and Chief Executive Officer of
Novartis U.S. Corporation. Both Mr. Clark and Mr. Costa possess
valuable commercial and operational expertise in the
biopharmaceutical industry, which will serve to augment the
strengths of the Board. Mr. Clark has served as an Operating
Partner of Genstar Capital since 2007. Prior to joining Genstar, he
served in numerous capacities at Icos Corporation, including
Director, Chief Executive Officer, President and Chairman of the
Board where he led the company through a period of considerable
growth, including the successful commercialization of Cialis(R)
(tadalafil). Mr. Clark also worked in key capacities for Abbott
Laboratories, retiring from Abbott as Executive Vice President and
a Board member. Mr. Clark has pharmaceutical commercialization
expertise and broad experience in sales, marketing and operational
roles with numerous healthcare and pharmaceutical companies. Mr.
Clark received his M.B.A. from Dartmouth College and his B.S. in
Finance from the University of Alabama. Mr. Costa held many roles
at Novartis, including President and Chief Executive Officer of
Novartis U.S. Corporation, Head of the Americas, and President and
Chief Executive Officer of Novartis Pharmaceutical Corporation.
Prior to joining Novartis, Mr. Costa worked at Johnson &
Johnson for 30 years, where he served as President of Janssen
Pharmaceutica, Executive Vice President, Global Franchise
Development, and was a member of Johnson & Johnson's Group
Operating Committee. Mr. Costa has held various sales and marketing
positions and has more than 20 years of general management
experience, having launched 10 pharmaceutical products in various
therapeutic areas in the U.S. market. Mr. Costa earned his M.B.A.
from Harvard Business School and is a graduate of the Sao Paulo
School of Business Administration. In addition to the new nominees,
the Company is nominating current directors Adrian Adams, Steven R.
Altman, Teresa Beck, Daniel M. Bradbury, Joseph C. Cook, Jr., Karin
Eastham, James R. Gavin III, M.D., Ph.D., Jay S. Skyler, M.D.,
Joseph P. Sullivan and James N. Wilson for re-election. With their
broad range of expertise, diverse perspectives, and in-depth
knowledge of Amylin's business, these directors will continue to
serve the best interests of all Amylin stockholders. "We are
confident that this is the right slate to represent the interests
of all our stockholders and to ensure that Amylin is well
positioned for sustainable long-term success," said James N.
Wilson, Lead Independent Director of Amylin's Board. "We engaged in
a thorough and comprehensive process to assemble this slate. After
considerable evaluation, we identified these nominees as those most
qualified to serve the needs of the Company and maximize value for
all Amylin stockholders." Two current directors, Howard E. (Ted)
Greene, Jr. and Ginger L. Graham, will not stand for re-election
this year. The Company greatly appreciates Mr. Greene's and Ms.
Graham's many years of dedicated service to build and grow the
Company, both as directors and former leaders of Amylin.
Stockholders may review more detailed biographies of all Amylin's
nominees in the Company's preliminary proxy statement filed today
with the Securities and Exchange Commission. About Amylin
Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines. Amylin
has developed and gained approval for two first-in-class medicines
for diabetes, SYMLIN(R) (pramlintide acetate) injection and
BYETTA(R) (exenatide) injection. Amylin's research and development
activities leverage the Company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin
is headquartered in San Diego, California. Further information on
Amylin Pharmaceuticals is available at http://www.amylin.com/. This
press release contains forward-looking statements about Amylin that
involve risks and uncertainties. The Company's actual results could
differ materially from those discussed herein due to a number of
risks and uncertainties, including risks and uncertainties that are
described in the Company's recently filed annual report on Form
10-K. Amylin disclaims any obligation to update these
forward-looking statements. Additional Information and Where to
Find It This release may be deemed to be solicitation material in
respect of the matters to be considered at the 2009 Annual Meeting
of Stockholders. Amylin will be filing a proxy statement with the
Securities and Exchange Commission ("SEC"). INVESTORS AND
SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER
RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Investors and securityholders will be able to receive
the proxy statement and other relevant documents free of charge at
the SEC's Web site at http://www.sec.gov/ or from Amylin Investor
Relations at 9360 Towne Centre Drive, San Diego, California 92121.
Participants in Solicitation Amylin and its directors and executive
officers and other members of management and employees may be
deemed to be participants in the solicitation of proxies in respect
of the matters to be considered at the 2009 Annual Meeting of
Stockholders. Information regarding the interests of Amylin's
directors and executive officers in the proxy contest will be
included in Amylin's definitive proxy statement. DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Alice Izzo of Amylin
Pharmaceuticals, +1-858-642-7272, Web Site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024